Our current results suggest that the methylation analysis of DOCK2 could potentially be used as an add-on to the D’Amico risk score in order to help improve the accuracy of PCa risk stratification, although further clinical validation in tissue biopsies is required to fully assess this. The gene discussed is DOCK2; the disease is posterior cortical atrophy.